CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Zegerid® +1 moredrug
Likely dose
Zegerid® 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00808769
NCT00808769Phase 4Completed
CompareCT.gov

Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression

Procter and Gamble·interventional·Posted Dec 16, 2008·Updated Jun 1, 2015

In Brief

A Phase 4 clinical trial evaluating Zegerid® and Prilosec OTC® for Normal Healthy Subject Population. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNormal Healthy Subject Population
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 16, 2008
Enrollment StartNov 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.5 years ago

Interventions

Zegerid®drug

capsule(20 mg omeprazole/sodium bicarbonate), single dose

Prilosec OTC®drug

Omeprazole-magnesium 20.6 mg, tablet, single dose